Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Letter to the Editor

Leukocyte telomere shortening in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality

Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed

Clin Mol Hepatol. 2024;30(4):982-986. Published online August 27, 2024

DOI: https://doi.org/10.3350/cmh.2024.0691

View: 1087 Download: 56 Web of Science: 1 Crossref: 1

Original Article

Burden of mortality from hepatocellular carcinoma and biliary tract cancers by race and ethnicity and sex in US, 2018–2023

Donghee Kim, Richie Manikat, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed

Clin Mol Hepatol. 2024;30(4):756-770. Published online June 24, 2024

DOI: https://doi.org/10.3350/cmh.2024.0318

View: 1949 Download: 98 Web of Science: 3 Crossref: 3

Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis

Harry Crane, Guy D. Eslick, Cameron Gofton, Anjiya Shaikh, George Cholankeril, Mark Cheah, Jian-Hong Zhong, Gianluca Svegliati-Baroni, Alessandro Vitale, Beom Kyung Kim, Sang Hoon Ahn, Mi Na Kim, Simone I Strasser, Jacob George

Clin Mol Hepatol. 2024;30(3):436-448. Published online April 16, 2024

DOI: https://doi.org/10.3350/cmh.2024.0109

View: 4856 Download: 281 Web of Science: 9 Crossref: 11

Current Burden of Steatotic Liver Disease and Fibrosis among Adults in the United States, 2017-2023

Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed

Received November 3, 2024 Accepted November 26, 2024

DOI: https://doi.org/10.3350/cmh.2024.0987 [Accepted]

View: 1351 Download: 263 Crossref: 1

1 |

Viewed By 6146	MAFLD: How is it different from NAFLD?
Viewed By 5249	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4973	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 4166	Examining the therapeutic landscape of beta-blockers in portal hypertension
Viewed By 3941	Gut microbiome and metabolome signatures in liver cirrhosis-related complications

Cited By 272	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 225	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 154	MAFLD: How is it different from NAFLD?
Cited By 79	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 76	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search